Zhongxin Finance, January 15 (Gong Hongyu) "Three yams are harvested and made into Jiuzhuan pills." The traditional Chinese medicine culture, which originated from Shennong's tasting of hundreds of herbs, is not only a treasure of ancient Chinese science, but also condenses the millennium of the Chinese nation. Come from the concept of health and the benevolence of doctors.
As traditional Chinese medicine enters a new development cycle, epidemic prevention and sustainable development have become new topics for traditional Chinese medicine enterprises.
The "14th Five-Year Plan" and the outline of the long-term goals for 2035 put forward that it is necessary to promote the inheritance and innovation of traditional Chinese medicine, adhere to the equal emphasis and complementary advantages of traditional Chinese medicine and western medicine, and vigorously develop the cause of traditional Chinese medicine.
In the face of opportunities and challenges, how can pharmaceutical companies solve the problem and achieve high-quality and sustainable development?
As a leading enterprise in the field of traditional Chinese medicine, Yiling Pharmaceutical delivered a perfect answer with innovation and responsibility.
"Traditional Chinese Medicine Stars" under the Epidemic
The gear of time is set back two years ago. The prevention and control of new coronary pneumonia has brought the "Lianhua" series of products represented by Lianhua Qingwen into the public eye again, and the Lianhua breathing health package has become popular in thousands of households.
And the soil that nurtured this "star" product line is Yiling Pharmaceutical.
Produced from innovative consciousness and supported by evidence-based medical research, Lianhua Qingwen is one of the most representative innovative patented traditional Chinese medicines developed by Ling Pharmaceutical.
In 2009, when influenza A (H1N1) broke out, researchers launched an evidence-based medical study on "Lianhua Qingwen Capsules for Influenza A H1N1 Influenza", and collected a large number of cases, covering all major age groups and various symptoms of influenza A. H1N1 influenza patients have created a precedent for evidence-based medical research on anti-influenza Chinese patent medicines.
In order to cope with the challenges of COVID-19, Lianhua Qingwen continued the tradition of evidence-based medicine research.
The "Prospective, Randomized, Controlled, Multi-Center Clinical Study of Traditional Chinese Medicine Lianhua Qingwen in the Treatment of Novel Coronavirus Pneumonia" was jointly participated by more than 20 new coronary pneumonia hospitals including Wuhan University People's Hospital, Wuhan Jinyintan Hospital, and the First Affiliated Hospital of Guangzhou Medical University. "It proves that Lianhua Qingwen Capsules can improve clinical symptoms in the treatment of patients with new coronary pneumonia.
In April 2020, based on the exact basic and clinical research evidence of Lianhua Qingwen, the State Food and Drug Administration approved Lianhua Qingwen to increase the indication of "new coronavirus pneumonia mild and common".
At present, Lianhua Qingwen has been approved for listing in more than 20 countries and regions.
It is worth mentioning that in the face of the new crown epidemic sweeping the world, Yiling has not only donated medicines and anti-epidemic materials to many epidemic-stricken areas in China, but also donated more than 10 million yuan of anti-epidemic materials to Iraq, Italy, Brazil and other overseas countries, passing on to the world. The corporate tenet of "inheriting innovation and benefiting mankind".
When it comes to corporate social responsibility, the relevant person in charge of Yiling Pharmaceutical said that if one party is in trouble, all parties support it.
The development of an enterprise is inseparable from the party and the government, as well as the care and support from all walks of life. Therefore, enterprises must repay and feed back to the society.
Theoretical innovation of collateral disease drives the research and development of patented traditional Chinese medicine
The truth-seeking and innovation path of Yiling Pharmaceutical is far more than that.
At present, cardiovascular and cerebrovascular diseases, diabetic microvascular diseases, etc. have become major diseases that seriously endanger human health, and these diseases all have microvascular diseases, and microvascular diseases are highly related to the collaterals of traditional Chinese medicine.
In this regard, Yiling Pharmaceutical has systematically built a theoretical system of collateral diseases, created a new discipline of collateral diseases in traditional Chinese medicine, established the State Key Laboratory of Collateral Diseases of the State Administration of Traditional Chinese Medicine, and the State Key Laboratory of Collateral Disease Research and Innovative Traditional Chinese Medicine. Relevant research has won the National Science and Technology Award six times, among which the project "Construction of TCM Context Theory and Its Guidance for the Prevention and Treatment of Microvascular Diseases" won the first prize of the National Science and Technology Progress Award in 2019.
This theory puts forward the core theory of the context theory, the Yingwei theory, establishes the clinical syndrome differentiation and diagnosis standard, and the medication rules, forms a systematic theory to guide the clinical practice, and opens up a new way to guide the prevention and treatment of cardiovascular and cerebrovascular diseases and diabetic vascular complications.
Under the guidance of this theory, three Chinese patent medicines for dredging collaterals and treating cardiovascular diseases—Tongxinluo Capsules, Shensong Yangxin Capsules, and Qili Qiangxin Capsules have solved many major problems in the international medical community.
With the continuous in-depth research of the theory of collateral disease by Yiling Pharmaceutical, the clinical application of traditional Chinese medicine guided by the theory of collateral disease has become clearer, and 13 innovative patented traditional Chinese medicines have been developed, which are used in cardiovascular and cerebrovascular diseases, diabetes, respiratory diseases, tumors. , neuropsychiatric system diseases and other major intractable diseases have achieved remarkable curative effect.
In the two years from 2020 to 2021 alone, Yiling Pharmaceutical has been approved three innovative patented traditional Chinese medicines: Lianhua Qingke Tablets, Yishen Yangxin Anshen Tablets, Jieyu Chufan Capsules, and all three varieties are deployed in clinical trials that have not been met. areas with high demand and large market space.
Among them, Lianhua Qingke Tablets is another innovative traditional Chinese medicine for the respiratory system developed by applying the theory of collateral diseases in traditional Chinese medicine after Lianhua Qingwen. It solves the clinical problems that sputum blocks the trachea and affects the function of pulmonary ventilation in a variety of infectious or infectious diseases of the respiratory system.
Lianhua Qingke Tablets was approved in May 2020, and at the end of 2020, it was included in the 2020 edition of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" for the first time through medical insurance negotiations.
The product's "resolving phlegm and relieving cough" effect and Lianhua Qingwen Capsules/Granule's "clearing and detoxifying" effect on viruses, bacteria and inflammation have a synergistic effect, and have a good ventilation and ventilation function in solving major infectious or infectious diseases of the respiratory system. Important clinical value and application prospects.
Yishen Yangxin Anshen Tablet relieves insomnia-related symptoms, and also improves symptoms such as dreaminess, palpitations, fatigue, forgetfulness, dizziness, and weak waist and knees.
The main functions of Jieyu Chufan Capsules include relieving stagnation and resolving phlegm, clearing heat and eliminating vexation, and can be used to improve symptoms such as depression, restlessness, foreign bodies in the throat, loss of appetite, and easy sighing.
In recent years, Yiling Pharmaceutical has been actively deploying drugs in the field of nervous system, which not only provides new treatment options for these two types of patients, but also brings new growth points to the company.
"In the future, the company will be based on a new stage of development, implement the concept of integrating traditional Chinese and Western medicine, create a new pattern of traditional Chinese medicine health industry, effectively promote the process of modernization, industrialization and internationalization of traditional Chinese medicine, solve the medical problems that people's livelihood concerns, and serve the common people. Develop new and more innovative patented traditional Chinese medicines that satisfy them." said Yiling, the person in charge.
The "innovative" DNA behind sustainable development
From a single traditional Chinese medicine to the whole industry chain of traditional Chinese medicine, chemical medicine, and big health, Yiling Pharmaceutical is the best interpretation of the spirit of innovation.
With 30 years of accumulation and accumulation, Yiling has explored a unique innovative patented traditional Chinese medicine research and development, production and sales model, and the core competitiveness of patented traditional Chinese medicine research and development driven by the theoretical innovation of collateral diseases.
"In recent years, the company's R&D team has continued to grow, and R&D investment has also increased significantly every year. Our R&D investment in 2020 reached 737 million yuan, ranking first among traditional Chinese medicine companies. In the first three quarters of 2021, R&D expenses were 538 million yuan. Yuan, an increase of 37.86% year-on-year." Wang Hongtao, vice president of Yiling Pharmaceutical Research Institute, introduced.
As he said, since its establishment, Yiling Pharmaceutical has always regarded scientific and technological innovation as the core force of the enterprise. Up to now, the scale of Yiling's entire R&D team has reached nearly 2,000 people. Elite talents with postdoctoral and associate senior titles or above.
It is understood that the Yiling Medical Research Institute has also successively established state-level scientific research platforms such as the State Key Laboratory of Collateral Disease Research and Innovative Traditional Chinese Medicine, the State Key Research Office of the State Administration of Traditional Chinese Medicine (cardio-cerebrovascular collateral disease), etc. More than 90 provincial and ministerial-level topics.
Yiling researchers are doing experiments.
In addition to scientific and technological innovation, Yiling is also a vanguard in the transformation and practice of health concepts.
In recent years, people's demand for health has developed from "disease treatment" to "disease prevention". In response, Yiling Pharmaceutical innovatively proposed the eight-character health culture of "draining collaterals, nourishing essence, moving body, and calming spirit", and developed The series of products that regulate blood sugar, lower blood pressure, reduce lipids and lose weight, laxative, detoxify, and regulate viscera, etc., series of products for dredging collaterals and healthy heart and brain, and series of products for calming the mind and helping sleep and improving mood, etc., let traditional Chinese medicine beat with the pulse of the times.
During the 17 years of joining Yiling, Wang Hongtao participated in the "Ultrafine Pulverization (Micron) Technology and Application of Insect Drugs" won the second prize of the 2007 National Technology Invention Award; "Research on the Treatment of Influenza with Chinese Medicine Lianhua Qingwen" won the 2011 Annual The second prize of National Science and Technology Progress Award.
He also completed the National "Eleventh Five-Year" Support Plan "Research on the Action Mechanism of Tongluo Compound Traditional Chinese Medicine Qili Qiangxin Capsule", the National "Twelfth Five-Year" Major New Drug Creation Project "Anti-arrhythmic Traditional Chinese Medicine Large Variety Shensong" Yangxin Capsule Technical Transformation” and other major scientific research projects.
Talking about the countless honors he has won together with Yiling Pharmaceutical, Wang Hongtao said, "This sense of honor and achievement cannot be exchanged for money." In him, we see Yiling who is brave in innovation and daring to undertake. The spirit is passing on and flowing.
(Finish)